Evidence map›Paper›PMID 22669576›Full record

ArticleCancer biology & therapy2012

Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type.

Min Zhao, Patrick C Sachs, Xu Wang, Catherine I Dumur, Michael O Idowu, Valentina Robila, Michael P Francis, Joy Ware, Matthew Beckman, Aylin Rizki and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Long term observation ofRegenerative therapy · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Min ZhaoDepartment of Pathology, Virginia Commonwealth University, Richmond, Virginia, USA.
Patrick C Sachs
Xu Wang
Catherine I Dumur
Michael O Idowu
Valentina Robila
Michael P Francis
Joy Ware
Matthew Beckman
Aylin Rizki
Shawn E Holt
Lynne W Elmore
University of Richmond · USVirginia Commonwealth University · USLifenet Health · USRegenerative Medicine Institute · MXVCU Massey Comprehensive Cancer Center

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
VCU Neuroscience Center Core GrantP30NS047463 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVLISHOCK, JOHN T · 2003 to 2013
$5.0M
Genomic Instability and Senescence in CancerK01CA105050 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ELMORE, LYNNE W · 2005 to 2009
$695k
NCI NIH HHS K01 CA105050NCI NIH HHS K01 CA105050-01A131NCI NIH HHS P30 CA016059NINDS NIH HHS 5P30NS047463NINDS NIH HHS P30 NS047463
6 · The paper itself

Abstract

Data are accumulating to support a role for adipose-derived mesenchymal stem cells (MSCs) in breast cancer progression; however, to date most studies have relied on adipose MSCs from non-breast sources. There is a particular need to investigate the role of adipose MSCs in the pathogenesis of basal-like breast cancer, which develops at a disproportionate rate in pre-menopausal African-American women with a gain in adiposity. The aim of this study was to better understand how breast adipose MSCs (bMSCs) contribute to the progression of basal-like breast cancers by relying on isogenic HMT-3255 S3 (pre-invasive) and T4-2 (invasive) human cells that upon transplantation into nude mice resemble this tumor subtype. In vitro results suggested that bMSCs may contribute to breast cancer progression in multiple ways. bMSCs readily penetrate extracellular matrix components in part through their expression of matrix metalloproteinases 1 and 3, promote the invasion of T4-2 cells and efficiently chemoattract endothelial cells via a bFGF-independent, VEGF-A-dependent manner. As mixed xenografts, bMSCs stimulated the growth, invasion and desmoplasia of T4-2 tumors, yet these resident stem cells showed no observable effect on the progression of pre-invasive S3 cells. While bMSCs form vessel-like structures within Matrigel both in vitro and in vivo and chemoattract endothelial cells, there appeared to be no difference between T4-2/bMSC mixed xenografts and T4-2 xenografts with regard to intra- or peri-tumoral vascularity. Collectively, our data suggest that bMSCs may contribute to the progression of basal-like breast cancers by stimulating growth and invasion but not vasculogenesis or angiogenesis.

Indexed as

Adipose TissueAnimalsAntigens, CDBone Marrow CellsBreast NeoplasmsCell Line, TumorChemotaxisFemaleFibroblast Growth Factor 2HumansHuman Umbilical Vein Endothelial CellsMammary Glands, HumanMatrix Metalloproteinases, SecretedMesenchymal Stem CellsMiceMice, NudeAntigens, CDFibroblast Growth Factor 2Matrix Metalloproteinases, SecretedVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID22669576
PMCPMC3399703
OpenAlexW2015648727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.